Aprogen Biologics Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Jeong-Chool Kim
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | no data |
Recent management updates
Recent updates
Risks Still Elevated At These Prices As Aprogen Biologics Inc. (KRX:003060) Shares Dive 26%
Jun 20
More Unpleasant Surprises Could Be In Store For Aprogen Biologics Inc.'s (KRX:003060) Shares After Tumbling 28%
Apr 18We Wouldn't Rely On Aprogen pharmaceuticalsInc's (KRX:003060) Statutory Earnings As A Guide
Jan 16Aprogen pharmaceuticals,Inc.'s (KRX:003060) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Dec 20
Is Aprogen pharmaceuticalsInc (KRX:003060) A Risky Investment?
Nov 24CEO
Jeong-Chool Kim
no data
Tenure
Jeong-Chool Kim serves as the Chief Operating Officer of Aprogen, Inc. Jeong Chul Kim serves as Chief Executive Officer of Gen-Exel Medical Inc. and Aprogen pharmaceuticals,Inc. (formerly known as Schnell...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 08:20 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aprogen Biologics Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|